AU1067695A - Use of lithium compounds in the treatment of cardiac insufficiency - Google Patents
Use of lithium compounds in the treatment of cardiac insufficiencyInfo
- Publication number
- AU1067695A AU1067695A AU10676/95A AU1067695A AU1067695A AU 1067695 A AU1067695 A AU 1067695A AU 10676/95 A AU10676/95 A AU 10676/95A AU 1067695 A AU1067695 A AU 1067695A AU 1067695 A AU1067695 A AU 1067695A
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- lithium compounds
- cardiac insufficiency
- sequelae
- angiotensin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 150000002642 lithium compounds Chemical class 0.000 title abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the use of lithium compounds alone or in combination with ACE inhibitors and/or receptor antagonists of angiotensin II in the treatment of cardiac insufficiency including its sequelae, with a view in particular to reducing the mortality due to the associated cardiovascular disorders.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4340437A DE4340437C1 (en) | 1993-11-27 | 1993-11-27 | Use of lithium compounds for the treatment of heart failure including its complications |
| DE4340437 | 1993-11-27 | ||
| PCT/EP1994/003920 WO1995014490A1 (en) | 1993-11-27 | 1994-11-26 | Use of lithium compounds in the treatment of cardiac insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1067695A true AU1067695A (en) | 1995-06-13 |
Family
ID=6503584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU10676/95A Abandoned AU1067695A (en) | 1993-11-27 | 1994-11-26 | Use of lithium compounds in the treatment of cardiac insufficiency |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0730471B1 (en) |
| AT (1) | ATE200983T1 (en) |
| AU (1) | AU1067695A (en) |
| DE (2) | DE4340437C1 (en) |
| WO (1) | WO1995014490A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19530319A1 (en) * | 1995-08-17 | 1997-02-20 | Woerwag Pharma Gmbh | Use of orotic acid to treat patients indicated for heart transplantation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386072A (en) * | 1981-06-26 | 1983-05-31 | Horrobin David F | Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor |
| ATE148632T1 (en) * | 1990-05-11 | 1997-02-15 | Pfizer | SYNERGISTIC THERAPEUTIC COMPOSITIONS AND METHODS |
-
1993
- 1993-11-27 DE DE4340437A patent/DE4340437C1/en not_active Expired - Fee Related
-
1994
- 1994-11-26 WO PCT/EP1994/003920 patent/WO1995014490A1/en not_active Ceased
- 1994-11-26 DE DE59409746T patent/DE59409746D1/en not_active Expired - Fee Related
- 1994-11-26 AU AU10676/95A patent/AU1067695A/en not_active Abandoned
- 1994-11-26 AT AT95901441T patent/ATE200983T1/en not_active IP Right Cessation
- 1994-11-26 EP EP95901441A patent/EP0730471B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE59409746D1 (en) | 2001-06-13 |
| EP0730471A1 (en) | 1996-09-11 |
| DE4340437C1 (en) | 1995-05-24 |
| WO1995014490A1 (en) | 1995-06-01 |
| EP0730471B1 (en) | 2001-05-09 |
| ATE200983T1 (en) | 2001-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9915134A (en) | Co-therapy and combination therapy for the treatment of cardiovascular disorders in an individual, and composition | |
| NZ310730A (en) | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure | |
| CA2251331A1 (en) | Calcilytic compounds | |
| YU53899A (en) | Use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders | |
| AU7928087A (en) | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs | |
| AU1970095A (en) | Ring electrode construction and implantable leads using the same | |
| AU1690399A (en) | Neovascularization inhibitor containing dienogest as the active ingredient | |
| EP0412594A3 (en) | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin ii antagonists | |
| AU9058591A (en) | Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy | |
| ZA941525B (en) | Use of riluzole in the treatment of nero-AIDS | |
| EP0711162A4 (en) | Imidazole 5-position substituted angiotensin ii antagonists | |
| AU4396993A (en) | Dipeptidyl peptidase-I, cloning it, and therapeutic agents containing inhibitors thereof | |
| AU3107795A (en) | Inhibitors of the benzamidine type | |
| AU4163693A (en) | Angiotension II receptor antagonists for the treatment of disturbances in cardiac rhythm | |
| WO1993020839A3 (en) | Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality | |
| EA200100951A1 (en) | COMBINED THERAPY WITH INHIBITOR ANGIOTENZIN-CONVERTING ENZYME AND EPOXYSTROID ANTAGONIST ALDOSTERONE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
| AU4668289A (en) | Heteroazabenzobicyclic carboxamide 5-ht3, antagonists | |
| EP0635263A3 (en) | Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue. | |
| AU3745895A (en) | Use of gaba antagonists in the treatment of emesis | |
| AU9084191A (en) | Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke | |
| CA2055948A1 (en) | Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria | |
| EP0858262A4 (en) | Thrombin inhibitors | |
| AU1067695A (en) | Use of lithium compounds in the treatment of cardiac insufficiency | |
| WO1996024373A3 (en) | Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist | |
| NO20013459D0 (en) | Use of agiotensin II receptor antagonists in the treatment of acute myocardial infarction |